The Affordable Care Act’s Impact in Reducing the Uninsured Rate in America & the Upcoming Health Insurance Cliff
In March 2010, President Barack Obama signed the Patient Protection & Affordable Care Act, commonly known as the ACA or Obamacare, into law. One of the legislation’s main goals was to reduce the number of Americans lacking health insurance coverage. Between the law’s passage in 2010 and 2023, the number […]
EMTALA in the Age of Rising Abortion Bans
Following the decision in Dobbs v. Jackson Women’s Health Organization in 2022, abortion bans have been popping up in states across the country. Many states have qualified their bans with exceptions based on the gestational age of the pregnancy, assault, or medical necessity. However, for 12 states, the exceptions, if […]
M&A Momentum in the Medical Device Industry
From EpiPen smartphone cases to portable kidney dialysis, the MedTech industry revolutionizes access to life saving care for patients. Robust market innovation has improved personalized treatments, reduced time in hospitals, and lowered healthcare costs. In the past year, high value investments and acquisitions have gained significant traction as businesses seek […]
DTC Advertising Under Fire: A Turning Point for Drug Promotion?
The Trump Administration has taken assertive steps to rectify the overmedicalization of American citizens by increasing oversight of Direct-to-Consumer (“DTC”) prescription drug advertising. Specifically, President Trump delegated authority to the Food and Drug Administration (“FDA”) to implement stringent regulations to ensure patients receive balanced information. The Administration has emphasized that […]
The Future of Abortion Pill Mifepristone Now Uncertain as it Faces a New Missouri District Judge
The US District Court for the Eastern District of Missouri is the new battleground for the legal fight over access to the abortion pill Mifepristone. This development comes after the Supreme Court remanded Judge Matthew Kacsmaryk’s injunction against the FDA’s current regulations on the drug last summer, ruling the case […]
